Efficacy of Applying Kanglaite Injection under Incentive Nursing Intervention in Treating Patients with Advanced Penile Carcinoma and Its Effect on Treatment Compliance

Abstract

Objective. To explore the efficacy of applying Kanglaite (KLT) injection under incentive nursing intervention (INI) in treating patients with advanced penile carcinoma and its effect on patient treatment compliance. Methods. The clinical data of 120 patients with advanced penile carcinoma treated in the Affiliated Hospital of Southwest Medical University from February 2019 to February 2020 were retrospectively analyzed, and the patients were equally divided into the experimental group (n = 60) and control group (n = 60) according to their admission order. All patients received the KLT injection treatment; those in the control group accepted the conventional nursing; and on this basis, those in the experimental group accepted INI, including psychological nursing intervention, which was conducted concurrently with the treatment, to compare their short-term efficacy, treatment compliance, degree of cancer-related fatigue (Brief Fatigue Inventory), and negative emotion scores (Hospital Anxiety and Depression Scale) between the two groups. Results. Compared with the control group, the experimental group presented a significantly higher objective remission rate (58.3%) ( P < 0.05 ), higher rates of excellent and good treatment compliance ( P < 0.05 ), and lower degree of cancer-related fatigue and negative emotion scores ( P < 0.001 ). Conclusion. INI can improve the negative emotions in patients with advanced carcinoma of the penis, alleviate their degree of cancer-related fatigue, promote their treatment compliance, and achieve a more significant efficacy of applying the KLT injection treatment, so it should be promoted in practice.

An icaritin-loaded microemulsion based on coix oil for improved pharmacokinetics and enhanced antitumor efficacy

“…This injection preparation could improve the antitumor effect of the CSO to a certain extent. Nevertheless, for IC, the poor solubility and oral bioavailability limited the full play of its antitumor effect (Zhan et al., 2012 ; Wu et al., 2018 ; J. Wang et al., 2021 ).…”